Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12433742 | 0.84 | SCN5A (0.46) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL10509506 | 0.83 | MTNR1A (0.46) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL2207267 | 0.82 | MTNR1A (0.47) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL2206369 | 0.82 | MTNR1A (0.47) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL6068496 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL6068403 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL6068402 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL2069498 | 0.80 | MTNR1A (0.51) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL2069117 | 0.80 | MTNR1A (0.51) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL2284298 | 0.79 | MTNR1A (0.62) | MTNR1AMTNR1BKMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755649-A1 | USE OF 3-(R)-[3-(2-METHOXYPHENYLTHIO)-2-(S)-METHYLPROPYL]AMINO-3,4-DIHYDRO- 2H-1,5-BENZOXATHIEPINE FOR PREVENTING AND/OR TREATING CARDIOTOXIC EFFECTS CAUSED BY CHEMOTHERAPY AND/OR RADIATION | Pierre Fabre Médicament (FR) | 2014-07-23 | — | — | EP | claimed |
| WO-2013037905-A1 | USE OF 3-(R)-[3-(2-METHOXYPHENYLTHIO)-2-(S)-METHYLPROPYL]AMINO-3,4-DIHYDRO- 2H-1,5-BENZOXATHIEPINE FOR PREVENTING AND/OR TREATING CARDIOTOXIC EFFECTS CAUSED BY CHEMOTHERAPY AND/OR RADIATION | PIERRE FABRE MEDICAMENT (FR) | 2013-03-21 | — | — | WO | claimed |
| WO-2022249006-A1 | USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-12-01 | — | — | WO | disclosed |
| US-20220340573-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4065228-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | Novartis AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| US-11427586-B2 | 1,2,4-oxadiazole derivatives as liver X receptor agonists | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| CN-114746149-A | 1,2, 4-oxadiazole derivatives as liver X receptor agonists | 诺华股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220064164-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2021105857-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064164-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NR1H4, GPBAR1, NR1I2 | MTNR1A 23/4885MTNR1B 36/4885KMT2A 4687/4885 |
| US-11427586-B2 | 1,2,4-oxadiazole derivatives as liver X receptor agonists | NR1H4, GPBAR1, NR1I2 | MTNR1A 23/4885MTNR1B 36/4885KMT2A 4687/4885 |
| US-20220340573-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NR1H4, GPBAR1, NR1I2 | MTNR1A 23/4885MTNR1B 36/4885KMT2A 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.